Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Revisiting accessible therapies for the management of Myelodysplastic Syndromes: A retrospective analysis of danazole, nandrolone or both.

Alejandra De Las Fuentes, Jorge Montemayor, Héctor Alejandro Vaquera Alfaro et al. Nov 03, 2025 pp. 7371-7371 10.1182/blood-2025-7371

Abstract “Revisiting accessible therapies for the management of myelodysplastic syndromes: a retrospective analysis of danazole, nandrolone...

IFNγ-driven MHC class II expression by intestinal epithelial cells dictates local cytolytic Th1 cell differentiation and intestinal stem cell loss

Motoko Koyama, Albert Yeh, Kathleen Ensbey et al. Nov 03, 2025 pp. 159-159 10.1182/blood-2025-159

Abstract Allogeneic hematopoietic stem cell / bone marrow transplantation (hereafter BMT) is a curative therapy for malignant and non-malign...

Aplastic anemia mortality in the United States (1999–2023): Trends, disparities, and public health implications

Saad Khan, Madho Mal, neha waseem et al. Nov 03, 2025 pp. 7996-7996 10.1182/blood-2025-7996

Abstract Background: Aplastic anemia is a rare, life-threatening hematological disorder characterized by bone marrow failure and pancytopeni...

CAR-T with ICOS costimulation lacks therapeutic efficacy in patient due to strong trogocytosis and failure of expansion

Yongxia Wu, Allison Pugel, Katie Palen et al. Nov 03, 2025 pp. 2346-2346 10.1182/blood-2025-2346

Abstract Background CAR-T cell therapy targeting B-cell antigens has become an established strategy for relapsed hematol...

Understanding the essential thrombocythemia diagnosis journey, treatment experience, disease burden, and unmet need: Insights from a qualitative interview study with patients in the United States

Xiaoqin Yang, Mavis Obeng-Kusi, Katie Miller et al. Nov 03, 2025 pp. 8161-8161 10.1182/blood-2025-8161

Abstract Background: Essential thrombocythemia (ET) is a rare, chronic myeloproliferative neoplasm characterized by sustained elevated plate...

Latency between detectable low-level measurable residual disease (MRD) by next-generation sequencing and overt relapse following flow cytometry MRD-negative remission in patients with acute lymphoblastic leukemia: Implications for the optimal frequency of MRD monitoring

Trevor Jamison, Elias Jabbour, Nitin Jain et al. Nov 03, 2025 pp. 1558-1558 10.1182/blood-2025-1558

Abstract Background: In patients (pts) with acute lymphoblastic leukemia (ALL), MRD by next-generation sequencing (NGS) for IG/TR has become...

Prognostic utility of myocardial work indices and biomarkers for identifying anthraquinone induced cardiotoxicity in hematopoietic stem cell transplantation

Xinyu Zuo, Jiexian Ma, Shuhong Shen et al. Nov 03, 2025 pp. 7614-7614 10.1182/blood-2025-7614

Abstract High-dose chemotherapy combined with autologous hematopoietic stem cell transplantation (auto-HSCT) remains a critical treatment mo...

Orelabrutinib plus anti-PD-1 antibody and fotemustine for newly diagnosed primary central nervous system lymphoma: Phase I/II results

Wanyue Zhao, Mengke Fan, Shanshan Ma et al. Nov 03, 2025 pp. 5465-5465 10.1182/blood-2025-5465

Abstract Background:Primary central nervous system lymphoma (PCNSL) is a rare and aggressive subtype of diffuse large B-cell lymphoma (DLBCL...

Characteristics and outcomes of pediatric hematopoietic stem cell transplantation-associated thrombotic microangiopathy: A retrospective single-center analysis

Taylor Luckie, Andrew Wahba, Haitham Al-Khatib et al. Nov 03, 2025 pp. 4197-4197 10.1182/blood-2025-4197

Abstract Background: Transplant-associated thrombotic microangiopathy (TA-TMA) is a heterogenous and life-threatening systemic complication...

The 2-year efficacy and safety of iptacopan monotherapy in patients with paroxysmal nocturnal hemoglobinuria with a history of aplastic anemia on concomitant immunosuppressive therapy who entered the roll-over extension program

Régis Peffault de Latour, Carlos de Castro, Anna Gaya et al. Nov 03, 2025 pp. 4978-4978 10.1182/blood-2025-4978

Abstract Introduction: Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, life-threatening disease characterized by complement-mediated he...

SGR-1505, a potent and selective MALT1 inhibitor with preliminary efficacy in BTKi exposed Waldenström macroglobulinemia (WM) and “double-exposed” CLL/SLL

Stephen Spurgeon, Vincent Ribrag, Vasile Musteata et al. Nov 03, 2025 pp. 3603-3603 10.1182/blood-2025-3603

Abstract Background: MALT1, a core subunit of the CBM complex (CARD11-BCL10-MALT1), plays an essential role in the NF-kB...

KIR3DL2-directed CAR T cell therapy for T cell malignancies

Federico Mario Aletti, Jinsheng Weng, Cuong Le et al. Nov 03, 2025 pp. 7621-7621 10.1182/blood-2025-7621

Abstract Chimeric antigen receptor (CAR) T cell therapy has transformed the treatment landscape for B cell malignancies and multiple myeloma...

Integrative clinical and molecular analysis of outcome in elderly African ancestry Acute Myeloid Leukemia

Jonathan Andreadakis, Olivia Wilkins, Gary Kupfer et al. Nov 03, 2025 pp. 1733-1733 10.1182/blood-2025-1733

Abstract Introduction: African Ancestry (AA) mediates inferior overall survival (OS) in Acute Myeloid Leukemia (AML), a feature highlighted...

ADAMTS13 variant (R1206K) exhibits increased VWF-cleaving activity and inhibition of thrombus formation under flow

Szumam Liu, X. Long Zheng Nov 03, 2025 pp. 4832-4832 10.1182/blood-2025-4832

Abstract Background: Thrombotic thrombocytopenic purpura (TTP) is a life-threatening thrombotic microangiopathy, caused by a severe deficien...

Final analysis of the evaluation of safety and efficacy of denosumab in patients with multiple myeloma and severe renal impairment: An IMWG bone subcommittee study

Evangelos Terpos, Ashraf Badros, Ioannis Ntanasis-Stathopoulos et al. Nov 03, 2025 pp. 1038-1038 10.1182/blood-2025-1038

Abstract Background Multiple myeloma (MM) patients often develop bone disease, predisposing them to skeletal-related events (SREs). Renal im...

Treatment selection and functional outcomes in treatment-related acute myeloid leukemia (tAML) and AML with myelodysplasia-related changes (MRC): A multicenter prospective cohort study

Vijaya Bhatt, Christopher Wichman, Joseph Maakaron et al. Nov 03, 2025 pp. 6381-6381 10.1182/blood-2025-6381

Abstract Introduction: Liposomal encapsulated daunorubicin/cytarabine (L-dauno/ara-C) is FDA approved for adults with tAML and AML MRC based...

Disparities related to myelofibrosis: A retrospective analysis of US mortality data

Aqsa Sorathia, Bassel Aldroubi, Hasan Munshi et al. Nov 03, 2025 pp. 2049-2049 10.1182/blood-2025-2049

Abstract Background Myelofibrosis (MF) is a rare clonal myeloproliferative neoplasm characterized by progressive bone ma...

Diagnostic test accuracy of serum ferritin and prevalence of iron deficiency in pregnant and menstruating individuals: A systematic review and meta analysis

Ali Choaib, Qais Hamarsha, Hassan Kawtharany et al. Nov 03, 2025 pp. 1130-1130 10.1182/blood-2025-1130

Abstract Background Serum ferritin is widely used to diagnose iron deficiency (ID) with or without anemia due to its correlation with iron s...

The contemporary adolescent and young adult sickle cell population in Malawi

Luke Eastburg, Kambe Banda-Zgambo, Timothy Mutafya et al. Nov 03, 2025 pp. 4747-4747 10.1182/blood-2025-4747

Abstract Sickle cell disease (SCD) is one of the most common inherited red blood cell disorders worldwide, with the majority of affected bir...

Atypical HUS: Diagnostic challenge and therapeutic success with eculizumab

Sumeet Yadav, Mohamed Warsame, Amar Lal Nov 03, 2025 pp. 6658-6658 10.1182/blood-2025-6658

Abstract Background: Atypical Hemolytic Uremic Syndrome (aHUS) remains a diagnostic challenge as it shares overlapping features of Thromboti...

A retrospective cross-sectional study to investigate femoral head avascular necrosis in sickle cell disease in Türkiye

Selma Ünal, Emel Gürkan, Meryem Şener et al. Nov 03, 2025 pp. 1162-1162 10.1182/blood-2025-1162

Abstract Introduction: Sickle cell disease (SCD) is one of the most prevalent hemoglobinopathies worldwide. This autosomal recessive disorde...

Age-related differences in outcomes and treatment patterns of iron deficiency anemia in patient's with crohn's disease

Karecia Byfield, Elvis Obomanu, Angimar Uriepero et al. Nov 03, 2025 pp. 2901-2901 10.1182/blood-2025-2901

Abstract Introduction Iron Deficiency Anemia (IDA) is a common extraintestinal manifestation of Crohn's Disease (CD) with reported prevalenc...

Developing a protocol for bloodless medicine patients undergoing transfusion-free kidney transplantation

Evani Patel, Patricia Locantore-Ford Nov 03, 2025 pp. 6688-6688 10.1182/blood-2025-6688

Abstract Bloodless medicine patients, including Jehovah's Witnesses (JW), have provided a natural case study for examining how adjuvant ther...

A real-world analysis of primary mediastinal large B-cell lymphoma: A single center study in China

Liu Zixian, Ming Gong Nov 03, 2025 pp. 7201-7201 10.1182/blood-2025-7201

Abstract Background Primary mediastinal large B-cell lymphoma (PMBCL) is a unique subtype of lymphoma, and the optimal t...

Disrupting CXCL12-DPP4-GPC3 axis redistributes leukemia stem cells and confines AML cells within bone marrow niche

Xunlei Kang, Chen Wang, Yi Pan et al. Nov 03, 2025 pp. 658-658 10.1182/blood-2025-658

Abstract Background: Acute myeloid leukemia (AML) is sustained by a rare population of leukemic stem cells (LSCs) that reside within protect...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page